HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

24 MONTH ENDOMETRIAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 24 month CRF: please complete any additional treatment details that were not captured at 6 or 12 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

©2025. This work is openly licensed by CC BY-NC-SA

Participant's Study ID		/		/[
Participant's date of bi	rth	d	d	m	m]	У	У	У	У	

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrhythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other	
chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Clinical diagnosis of depression		
Psychiatric Diagnosis (e.g. schizophrenia, bipo	elar disorder)	
Osteoarthritis		
Rheumatoid Arthritis		
Other Rheumatological Disease (systemic lumyositis, rheumatic polymyositis, scleroderma et		
HIV/AIDS		
Alcohol Abuse (or history of, must be accompa	nied by social, behavioural or medical com-	
Drug/Substance Abuse (or history of, must be medical complications)	e accompanied by social, behavioural or	
Morbid Obesity		
Other (please give details)		
Other (please give details)		
Other (please give details)		
s the participant pre or post menopause Pre menopause	? (please tick one box)	
·		
Post menopause Unknown		

Participant's Study ID / / /

	 ı		 _	
Participant's Study ID	/	/		
	•	•		

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why	
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery)		// 20			
Combined Chemo- radiotherapy	Combined chemo-radiotherapy Please also tick the boxes below/ overleaf to indicate which treat- ments were combined. If the combined treatments are not mentioned below/overleaf, please give details on line		// 20	// 20		
Chemotherapy	Carboplatin		// 20	//20		
	Carboplatin with paclitaxel		// 20	//20		
	CAP: cyclophosphamide, doxorubicin and cisplatin/carboplatin		// 20	// 20		
	Other chemotherapy (please describe)		// 20	// 20		
	Chemotherapy number of cycles	(please er	nter on line)			
Radiotherapy	External radiotherapy		//20	// 20		
	Combined external radiotherapy and brachytherapy (please also complete brachytherapy details overleaf)		//20	//20		
	Number of radiotherapy fractions	s (please e	enter on line)			
	Dose for each radiotherapy fraction (please enter on line)					

Participa	nt's Study ID	/	/		
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of oth- er treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Radiotherapy (cont.)	Brachytherapy LOW dose rate		// 20	// 20	
	Brachytherapy HIGH dose rate		// 20	// 20	
	Brachytherapy PULSED dose rate		//20	// 20	
Additional Treatment	If any additional treatment has been given please describe		// 20	// 20	
lere any of t	he treatments detailed	l above d	iven with nalli	ative intent?	

Were any of the treatments detailed above given with palliative intent?					
(please tick one box)	Yes	No	Unknown		
If yes, please indicate w	hich treatments	5?			

Participant's Study ID / / /
Has the participant had a local recurrence of their endometrial cancer? (please tick one box) Yes No Unknown
If the participant has had a local recurrence, on what date was the recurrence
diagnosed?
Since the participant's diagnosis of endometrial cancer, has there been any evidence of distant metastatic disease? (please tick one box)
Yes No Unknown
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:
Please provide details of the site(s) of distant metastatic disease:
s the participant taking part in a clinical trial? (please tick one box) Yes No Unknown
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in Name of clinical trial

Participant's Study ID /					
Since the participant's diagnosis of endome with another new primary cancer? (please					
Yes No	Unknown				
If you answered "yes" to the above question about the participant's new cancer diagno					
Type of cancer					
Date of diagnosis// 20					
Treatment received					
Date treatment ended (if finished)// 20					
What type of follow-up care is the particip					
Routine/regular hospital clinic based follo face-to-face or by telephone)	ow-up (medical or nurse led,				
Primary care based follow-up					
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)					
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?					

Participan	t's Study ID / /
· ·	ticipant been referred to any of the following services and/or had a ds Assessment? (please tick all that apply)
Participant	has been referred to palliative care services
If available	please give reason for referral (e.g. end of life care, symptom management)
Participant	has been referred to psychological services
If ticked, pleas	e provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant	has been referred to community services
Participant	has been referred for treatment related problems (e.g. urology,
gastroente	Ology) If ticked, please provide more details below:
Participant	has had an HNA (holistic needs assessment)
Participant'	ipant has died please give the date and cause of death: s date of death dd / mm / yyyyy rticipant's death
1) a)	
1) b)	
1) c)	
2)	
Cause of de	ath not known
Please add	d your name and signature and the date that you completed this CRF
Name	Signature
Data CRE	completed dd/mm//yyyyy